RG-NAH005 / Regen BioPharma - LARVOL DELTA

Regen BioPharma, Inc. examines combining cannabidiol (CBD) with its lead NR2F6 agonist to treat for inflammatory bowel disease (PRNewswire) - "Regen BioPharma...reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD)....'Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases'..."

Preclinical